Taught by leading experts in the field, this program provides a deep understanding of the core principles of tumor immunology and cancer immunotherapy as well as developing areas in the field including biomarker technology, validation and clinical integration; clinical trial design, data analysis and considerations for combination therapies.
The program is tailored to early-to-mid career scientists and clinicians in the field of cancer immunotherapy working in academic, clinical, industry and government settings as well as those new to the field.
Theme: New Dimensions of Therapeutic Antibodies. Annual Kunkel Memorial Lecturer: Tadatsugu Taniguchi, PhD, The University of Tokyo. He will be speaking about advances in the treatment of inflammatory diseases and cancer.
The Arthur L. Irving Family Foundation together with the Mass General Cancer Center are excited to announce the inaugural “Arthur L. Irving Family Foundation Cancer Immunology Symposium” to be held virtually, due to COVID-19. The Symposium will bring together 15 accomplished faculty mentors who are excited to share their discoveries and research career experience in cancer immunology with 40 promising young scientists (post-docs, starting PIs, and exceptional advanced graduate students).
Applicants were selected by a committee based on the applicant’s research achievements and plans, and recommendations by their mentors. The application deadline has passed. We are no longer accepting new applications at this time.
The first week will feature the opening ceremony, plenary sessions, major scientific sessions, and award lectures. All proffered abstracts that are accepted for presentation—including clinical trials and late-breaking abstracts—will also be presented in plenary sessions, minisymposia, and ePoster sessions during this week.
CIMT will take the opportunity to provide international participants with high-level scientific learning and knowledge exchange regardless of their location or travel restrictions. Details to come at www.meeting.cimt.eu.
This three-day conference will convene experts in immuno-oncology to discuss the latest research in the field. Topics under consideration will include how insights from the immune response to infection can inform our understanding of cancer immunotherapy, the COVID-19/Immuno-oncology interface, advances in multiple myeloma, cytokines, novel checkpoints and more.
The second week will feature education sessions, methods workshops, meet the expert sessions, and professional advancement sessions.
18 May – Day One: Discovery & Development: Cell Therapies & Combination Therapies / Biomarkers in Immuno-Oncology / Mechanisms & Novel Treatments in Autoimmunity
19 May – Day Two: Discovery & Development: Intratumoural Immunotherapies & Antibody Therapies / Translational & Preclinical Development / Immunotherapy: A Clinician’s Perspective.
The focus of the IRCI symposium allows prominent scientists and clinicians to present their recent data in the multidisciplinary area of immunology in cancer and/or infectious diseases. As in our prior 1st IRCI symposium in 2017, our goal is to keep the number of participants limited thereby driving increased discussion between leaders in the field and attendees, thus strengthening as well as defining immunological research and curative therapies in the near future.
The IRCI meeting is organized by researchers from two leading centers in Lyon, the CIRI and CRCL. The first edition gathered more than 340 people from all around the world. This 2021 edition will highlight the recent discoveries in innate and adaptive immunity, immuno-metabolism; immunotherapy and (epi)genetics.
The ESMO Congress is the yearly appointment in Europe for nearly 30,000 clinicians, researchers, oncology nurses, patient advocates, journalists and representatives of the pharmaceutical industry from all over the world to get together, learn about the latest advances in oncology and translate science into better cancer patient care.
The ESMO 2021 programme will be developed by a committee composed of more than 300 international experts and will span from basic research to the latest discoveries in immunotherapy of cancer, from oncology nursing to palliative care, from rare cancers to approval of medicines.
Paris will be the home of the ESMO annual congress for the first time, taking place from 17 to 21 September 2021 at the Paris Expo Porte de Versailles, France.
The Leipzig Immune ONcology (LION) Conference will bring together clinicians, scientists and industry to discuss latest developments and highlights on special issues of immune oncology. The annual meeting is organized by the Fraunhofer Institute for Cell Therapy and Immunology and the University Cancer Center of the University Hospital Leipzig.
The sessions of this new edition of the International Congress of Micro-immunotherapy will cover both clinical and research topics from the fields of immunology and metabolism.